Moleculin Biotech, Inc. financial data

Symbol
MBRX on Nasdaq
Location
Houston, TX
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2025 - Nov 13, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 122 % -59.3%
Debt-to-equity -1.55K % -3283%
Return On Equity 3.73K %
Return On Assets -257 % -155%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 50.9M shares +1596%
Common Stock, Shares, Outstanding 49.5M shares +1549%
Entity Public Float 9M USD -43.8%
Common Stock, Value, Issued 49K USD +1533%
Weighted Average Number of Shares Outstanding, Basic 37.3M shares +904%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 0 USD
Research and Development Expense 15.2M USD -23.5%
General and Administrative Expense 8.87M USD -0.11%
Operating Income (Loss) -24.2M USD +16.3%
Income Tax Expense (Benefit) 0 USD
Net Income (Loss) Attributable to Parent -51.4M USD -72.9%
Earnings Per Share, Basic -1 USD/shares +84%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 6.7M USD -28.7%
Assets, Current 7.89M USD -32.1%
Property, Plant and Equipment, Net 77K USD -59.5%
Operating Lease, Right-of-Use Asset 343K USD -23.8%
Other Assets, Noncurrent 900K USD
Assets 20.4M USD -13%
Accounts Payable, Current 2.12M USD -17%
Employee-related Liabilities, Current 1.35M USD -10.6%
Accrued Liabilities, Current 3.57M USD +17.2%
Liabilities, Current 5.68M USD +1.59%
Operating Lease, Liability, Noncurrent 258K USD -33.8%
Liabilities 47.3M USD +197%
Retained Earnings (Accumulated Deficit) -222M USD -46.3%
Stockholders' Equity Attributable to Parent -26.9M USD -255%
Liabilities and Equity 20.4M USD -13%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -4.56M USD +32.1%
Net Cash Provided by (Used in) Financing Activities 8M USD
Net Cash Provided by (Used in) Investing Activities 0 USD
Common Stock, Shares Authorized 500M shares +400%
Common Stock, Shares, Issued 49.5M shares +1549%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 3.44M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 6.7M USD -28.7%
Deferred Tax Assets, Valuation Allowance 38.6M USD +19.6%
Deferred Tax Assets, Gross 38.7M USD +19.5%
Operating Lease, Liability 478K USD -16.7%
Payments to Acquire Property, Plant, and Equipment 0 USD
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -45M USD -69.2%
Lessee, Operating Lease, Liability, to be Paid 566K USD -20.5%
Operating Lease, Liability, Current 132K USD +13.8%
Lessee, Operating Lease, Liability, to be Paid, Year Two 164K USD +3.15%
Lessee, Operating Lease, Liability, to be Paid, Year One 159K USD +8.9%
Operating Lease, Weighted Average Discount Rate, Percent 0.1 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 88K USD -36.2%
Lessee, Operating Lease, Liability, to be Paid, Year Three 141K USD -14%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 339K USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 61K USD -56.7%
Operating Lease, Payments 158K USD +21.5%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 113K USD -11.7%
Deferred Tax Assets, Net of Valuation Allowance 92K USD -17.9%
Share-based Payment Arrangement, Expense 1.63M USD -8.21%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%